Article History
Received: 20 October 2021
Accepted: 12 August 2022
First Online: 22 August 2022
Declarations
:
: K. Sawa receives payment for lectures from Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., and Nippon Boehringer Ingelheim Co., Ltd. I. Sato holds stack in Astellas Pharma Inc. and Daiichi Sankyo Co., Ltd.M. Takeuchi received a consultation fee from Eisai Co., Ltd. K. Kawakami received advisory fees from Shin Nippon Biomedical Laboratories, Ltd., JMDC Inc., Leber Inc. Kaken Pharmaceutical Co.,Ltd., and Advanced Medical Care Inc.; payment for lectures including service on speakers bureaus from Mitsubishi Corp., Mitsubishi Chemical Holdings Corp., Daiichi Sankyo Co., Ltd., Chugai Pharmaceutical Co., Ltd., Kyoto University Original Co., Ltd., McKinsey & Co. Inc., Nikkei Business Publications, Inc., Astellas Pharma Inc., AstraZeneca K.K., Mitsubishi Tanabe Pharma Corp., and IQVIA Services Japan K.K.; research funds from Sumitomo Dainippon Pharma Co., Ltd., Pfizer Inc., Stella Pharma Corporation, CMIC Co., Ltd., Suntory Beverage & Food Ltd., Eisai Co., Ltd., Kyowa Kirin Co., Ltd., Mitsubishi Corp. Ltd. and Real World Data, Co., Ltd.; and holds stock in Real World Data, Co., Ltd.